The Lifetime Health and Economic Burden of Smokeless Tobacco use in Bangladesh, India, and Pakistan: Results From ASTRAMOD

Author:

Coyle Kathryn1,Singh Prashant Kumar2ORCID,Kaushik Ravi3,Huque Rumana4ORCID,Khan Zohaib5ORCID,Mehrotra Ravi67ORCID,Siddiqi Kamran8ORCID,Pokhrel Subhash1ORCID

Affiliation:

1. Health Economics Research Group (HERG), Department of Health Sciences, Brunel University London , Uxbridge , UK

2. Division of Preventive Oncology and Population Health, ICMR-National Institute of Cancer Prevention and Research , Noida , India

3. Department of Physiology, Maulana Azad Medical College , New Delhi , India

4. ARK Foundation , Dhaka , Bangladesh

5. Office of Research, Innovation, and Commercialization, Khyber Medical University , Peshawar , Pakistan

6. Centre for Health Innovation and Policy (CHIP) Foundation , Noida , India

7. Division of Global Public Health, Brunel University London , Uxbridge , UK

8. Department of Health Sciences and Hull York Medical School, University of York , York , UK

Abstract

Abstract Introduction Under the current policy landscapes, the lifetime health and economic burden of smokeless tobacco (ST) products, consumed by over 297 million ST users in South Asia, is unknown. The aim of this study was to estimate the lifetime health effects and costs attributable to current and future ST use in Bangladesh, India, and Pakistan where the majority of ST users live. Aims and Methods We developed a Markov-based state-transition model (ASTRAMOD) to predict the lifetime costs of treatment of four diseases (oral, pharyngeal, esophageal cancers, and stroke) and disability-adjusted life years (DALYs), attributable to the current and future use of ST under existing ST policy scenario. Country-specific Global Adult Tobacco Surveys, life tables, and meta-analyses of South Asian and South East Asian studies were used to populate the model. A probabilistic sensitivity analysis evaluated the uncertainty in model predictions. Results If there were no change in the current ST policies, the lifetime ST-attributable treatment costs would be over US$19 billion in India, over US$1.5 billion in Bangladesh, and over US$3 billion in Pakistan. For all countries, the attributable costs are higher for younger cohorts with costs declining with increasing age for those over 50. The model predicted that a typical 15-year-old male adoloscent would gain 0.07–0.18 life years, avert 0.07–0.19 DALYs, and generate a cost-savings of US$7–21 on healthcare spending if ST policies were changed to eliminate ST use. Conclusions Policy interventions aimed at decreasing the uptake of ST and increasing quitting success have the potential to substantially decrease the economic and health burden of ST. Implications This study provides the most comprehensive estimates of the lifetime health and economic burden of ST by 5-year age and sex cohorts. This is also the first study that highlights the scale of health and economic burden of ST in Bangladesh, India, and Pakistan if there were no changes in the current ST policies. Policymakers and practitioners can use the reported data to justify their decisions to improve current ST policies and practices in their country. Researchers can use the ASTRAMOD methodology to estimate the impact of future ST policy changes.

Funder

UK government

Publisher

Oxford University Press (OUP)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3